Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...

Recursion can feel like magic until you understand its simple rules: a base case to stop, and a recursive call to repeat. By breaking problems into smaller versions of themselves, recursion makes ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki ...

Stream NBC 5 for free, 24/7, wherever you are. In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and ...